Dateline City:
NEW YORK
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb)
announced today the commencement, in connection with its previously
announced acquisition of Celgene Corporation (NASDAQ:CELG) (“Celgene”),
of an exchange offer for any and all outstanding notes (the “Celgene
Notes”) issued by Celgene for up to $19,850,000,000 aggregate principal
amount of new notes to be issued by Bristol-Myers Squibb (the
“Bristol-Myers Squibb Notes”) and cash.
Language:
English
Contact:
Media:Carrie L. Fernandez609-252-5222 [email protected] Investors:Tim Power609-252-7509 [email protected]
Ticker Slug:
Ticker: BMY Exchange: NYSE
Ticker: CELG Exchange: NASDAQ
read more